Filtered By:
Infectious Disease: COVID-19
Vaccination: Vaccines

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 391 results found since Jan 2013.

Vaccination, Acute Myocardial Infarction, and Ischemic Stroke After COVID-19 Infection
To the Editor We would like to highlight some key points about the recent article that reported that patients who received full vaccination against COVID-19 had a reduced risk of acute myocardial infarction (AMI) and ischemic stroke after COVID-19 diagnosis.
Source: JAMA - February 7, 2023 Category: General Medicine Source Type: research

Vaccination, Acute Myocardial Infarction, and Ischemic Stroke After COVID-19 Infection —Reply
In Reply We thank Dr Chu and colleagues for their comments about our Research Letter. Our analysis found that 2 doses of COVID-19 vaccine were associated with a reduced risk of AMI and ischemic stroke after COVID-19, using inverse probability treatment weighting to mitigate the imbalance in patient characteristics by vaccination status.
Source: JAMA - February 7, 2023 Category: General Medicine Source Type: research

BA1 Bivalent COVID-19 Vaccine Use and Stroke in England
This study investigates the association between bivalent COVID-19 vaccines and ischemic stroke, as well as the effect of simultaneous influenza vaccination on the association.
Source: JAMA - Journal of the American Medical Association - June 15, 2023 Category: General Medicine Source Type: research

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study
Conclusions Our estimated background rates help contextualise observed events of these potential adverse events of special interest and to detect potential safety signals related to COVID-19 vaccines.
Source: BMJ Open - December 17, 2021 Category: General Medicine Authors: Nasreen, S., Calzavara, A. J., Sundaram, M. E., MacDonald, S. E., Righolt, C. H., Pai, M., Field, T. S., Zhou, L. W., Wilson, S. E., Kwong, J. C. Tags: Open access, Public health, COVID-19 Source Type: research

Guidance Issued for Managing CVST After COVID-19 Vaccination
TUESDAY, May 11, 2021 -- In a report from the American Heart Association/American Stroke Association Stroke Council Leadership, published online April 29 in Stroke, recommendations are presented for the management of cerebral venous sinus thrombosis...
Source: Drugs.com - Pharma News - May 11, 2021 Category: Pharmaceuticals Source Type: news

Cerebrovascular Complications of COVID-19 and COVID-19 Vaccination
Circ Res. 2022 Apr 15;130(8):1187-1203. doi: 10.1161/CIRCRESAHA.122.319954. Epub 2022 Apr 14.ABSTRACTThe risk of stroke and cerebrovascular disease complicating infection with SARS-CoV-2 has been extensively reported since the onset of the pandemic. The striking efforts of many scientists in cooperation with regulators and governments worldwide have rapidly brought the development of a large landscape of vaccines against SARS-CoV-2. The novel DNA and mRNA vaccines have offered great flexibility in terms of antigen production and led to an unprecedented rapidity in effective and safe vaccine production. However, as mass vac...
Source: Circulation Research - April 14, 2022 Category: Cardiology Authors: Manuela De Michele Joshua Kahan Irene Berto Oscar G Schiavo Marta Iacobucci Danilo Toni Alexander E Merkler Source Type: research

Adverse events following COVID ‐19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia
ConclusionAvailable literature includes more studies with the BNT162b2 vaccine than mRNA-1273. Future studies must report mortality and adverse cardiovascular events by vaccine types.
Source: Immunity, Inflammation and Disease - March 17, 2023 Category: Allergy & Immunology Authors: Farah Yasmin, Hala Najeeb, Unaiza Naeem, Abdul Moeed, Abdul Raafe Atif, Muhammad Sohaib Asghar, Nayef Nimri, Maryam Saleem, Dhrubajyoti Bandyopadhyay, Chayakrit Krittanawong, Mohammed Mahmmoud Fadelallah Eljack, Muhammad Junaid Tahir, Fahad Wa Tags: REVIEW ARTICLE Source Type: research

One-Third of COVID-19 Survivors May Develop a Neuropsychiatric Disorder Within Months of Infection
One-third of individuals diagnosed with COVID-19 developed a psychiatric or neurological problem within six months of their diagnosis, according to astudy published Tuesday inThe Lancet Psychiatry. The prevalence of a post-COVID neurologic or psychiatric diagnosis was even greater among individuals with severe illness who had required hospitalization.“Given the size of the pandemic and the chronicity of many of the diagnoses and their consequences (for example, dementia, stroke, and intracranial hemorrhage), substantial effects on health and social care systems are likely to occur,” wrote Maxime Taque, Ph.D., of the Un...
Source: Psychiatr News - April 7, 2021 Category: Psychiatry Tags: anxiety COVID-19 electronic health records hospitalizations mood disorders neuropsychiatric disorders The Lancet Psychiatry Source Type: research

Large Vessel Stroke Linked to AstraZeneca COVID Vaccine Large Vessel Stroke Linked to AstraZeneca COVID Vaccine
The first cases of large vessel arterial occlusion strokes linked to the AstraZeneca COVID-19 vaccine have been described in the UK.Medscape Medical News
Source: Medscape Cardiology Headlines - May 26, 2021 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Potential  adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
AbstractReports of cerebral venous sinus thrombosis and intracranial hemorrhage (ICH) following the administration of coronavirus vaccines have raised concerns regarding their safety. Although no regulatory authority has recognized ICH as an adverse event associated with tozinameran (BNT162b2, Pfizer-BioNTech), fatal and non-fatal cases have been reported. In Japan, 10 fatal cases (five men and women) have been reported to date. Four of the five women died of ICH and the other died of aspiration pneumonia, whereas all five men died of causes other than stroke. This imbalance is incompatible with the mortality data on cardi...
Source: Journal of Pharmaceutical Policy and Practice - May 31, 2021 Category: Pharmaceuticals Source Type: research

Key Takeaways From the Latest Stroke Guidelines Key Takeaways From the Latest Stroke Guidelines
Dr Christoph Diener on six new publications whose recommendations cover topics ranging from blood pressure management to COVID-19 vaccinations.Medscape Neurology
Source: Medscape Neurology and Neurosurgery Headlines - October 13, 2021 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news

Unexplained arterial thrombosis: approach to diagnosis and treatment
We present a structured approach to diagnosis with consideration of common causes, including atherosclerosis and embolism, as well as uncommon causes, including medications and substances, vascular and anatomic abnormalities, systemic disorders, and thrombophilias. We highlight areas of management that have evolved within the past 5 years, including the use of dual-pathway inhibition in atherosclerotic disease, antithrombotic therapy selection in embolic stroke of undetermined source and left ventricular thrombus, the role of closure of patent foramen ovale for secondary stroke prevention, and the thrombotic potential of c...
Source: Atherosclerosis - December 10, 2021 Category: Cardiology Authors: Jori E May Stephan Moll Source Type: research